ORPHA:90038
Shiga toxin-associated hemolytic uremic syndrome
Also known as: D+ HUS · EHEC-HUS · Hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli · Hemolytic uremic syndrome with diarrhea · STEC-HUS · Shiga-like toxin-associated HUS · Stx-HUS · Typical HUS · Typical hemolytic uremic syndrome
Publications
1,758
Trials
3
Interventional, condition-specific
Researchers
1,244
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare thrombotic microangiopathy characterized by mechanical hemolytic anemia, thrombocytopenia, and renal dysfunction that is usually associated with prodromal enteritis caused by Shigella dysentriae type 1 or E. Coli.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019536
- UMLS:C1856143
Additional Mondo synonyms (7)
D+HUS · STEC Hemolytic Uremic Syndrome · Sxt-HUS · hemolytic-uremic syndrome with diarrhea · hemolytic-uremic syndrome with diarrhoea · typical HUS · typical hemolytic-uremic syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,758 matched papers (1,049 in last 10 years) Source
- Phenotype characterisedPresent
33 HPO annotations (e.g. Thrombocytopenia; Acute kidney injury; Microangiopathic hemolytic anemia) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
3 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
33
Associated phenotypes · MONDO:0019536
- Thrombocytopenia
- Acute kidney injury
- Microangiopathic hemolytic anemia
- Vomiting
- Diarrhea
Showing 5 of 33 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,758
1,758 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,758 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,049 in the last 10 years · low confidence
Phrase hits: 1,758 · MeSH hits: 0
Who's working on it?
1,244
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Balestracci A11 papers · 2026
Nephrology Unit, Hospital General de Niños Pedro de Elizalde, Montes de Oca 40, 1270, Autonomous City of Buenos Aires, Argentina.
Papers in Europe PMC - 02Alconcher LF8 papers · 2026
Pediatric Nephrology Unit, Hospital Interzonal General Dr. José Penna, Lainez, 8000, Bahía Blanca, Buenos Aires, 2401, Argentina.
Papers in Europe PMC - 03Ardissino G8 papers · 2026
Center for HUS Control, Prevention and Management, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122 Milano, Italy.
Papers in Europe PMC - 04Rivas M8 papers · 2026
Laboratorio Nacional de Referencia, Servicio Fisiopatogenia, Instituto Nacional de Enfermedades Infecciosas-ANLIS Dr. Carlos G. Malbrán, Ciudad Autónoma de Buenos Aires, Argentina.
Papers in Europe PMC - 05Dato L6 papers · 2026
Division of Pediatrics, Department of Health Sciences, Università del Piemonte Orientale, Novara.
Papers in Europe PMC - 06Principi I6 papers · 2026
Hospital Pediátrico Dr. Humberto J. Notti, Mendoza, Argentina.
Papers in Europe PMC - 07Zylberman V6 papers · 2026
Inmunova S.A, Gral. San Martín, Buenos Aires, Argentina.
Papers in Europe PMC - 08Colonna M5 papers · 2026
Inmunova SA, Ciudad Autónoma de Buenos Aires, Argentina.
Papers in Europe PMC - 09Liu Y5 papers · 2026
Department of Nephrology, The First Hospital of Jilin University, Changchun 130021, China.
Papers in Europe PMC - 10Mancuso MC5 papers · 2026
From the Center for HUS Prevention Control and Management at the Pediatric Nephrology Dialysis and Transplant Unit.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
3
interventional trials for this specific condition
3 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 38 trials are registered for hemolytic-uremic syndrome, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
3 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 86.7th percentile).
low confidence · 86.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
3 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06389474·RECRUITING·Efficacy of INM004 in Children With STEC-HUS
Not reviewed·Conditions: Hemolytic-Uremic Syndrome·Matched via name phrase
Broader category: hemolytic-uremic syndrome
38
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07308574·RECRUITING·Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
Not reviewed·Conditions: aHUS · Atypical Hemolytic Uremic Syndrome·Matched via name phrase
- NCT05805202·RECRUITING·Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy
Not reviewed·Conditions: Atypical Hemolytic Uremic Syndrome·Matched via name phrase
- NCT05726916·RECRUITING·Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome
Not reviewed·Conditions: Hypertensive Emergency-associated Hemolytic Uremic Syndrome·Matched via name phrase
- NCT05935215·RECRUITING·Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Not reviewed·Conditions: Atypical Hemolytic Uremic Syndrome·Matched via name phrase
- NCT05996731·RECRUITING·Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
Not reviewed·Conditions: Atypical Hemolytic Uremic Syndrome · Membranoproliferative Glomerulonephritis · Autosomal Dominant Polycystic Kidney · Healthy·Matched via name phrase
- NCT05684159·NOT YET RECRUITING·Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy
Not reviewed·Conditions: aHUS - Atypical Hemolytic Uremic Syndrome·Matched via name phrase
- NCT05219110·RECRUITING·Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
Not reviewed·Conditions: Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection · Hemolytic-Uremic Syndrome·Matched via name phrase
- NCT05795140·RECRUITING·Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Not reviewed·Conditions: Atypical Hemolytic Uremic Syndrome·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 4 · after dedupe 4 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 4 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (4)
- isrctn·ISRCTN10647845·No longer recruiting·Effectiveness of add-on group behavioral activation treatment for depression in psychiatric care
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN35641359·No longer recruiting·Study with S 81694 in perfusion in patients with solid tumors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98405441·No longer recruiting·Adjuvant therapy: colorectal cancer chemotherapy study (LIitännäishoito: Paksu- ja PeräsuoliSYövän SYtostaattiTerapiaTutkimus): comparison of 5-fluorouracil (5-FU) and leucovorin as bolus injection or continuous infusion with special emphasis on toxicity, cost-benefit, quality of life, effect of nutrition, changes in bacterial flora and prognostic factors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN66499946·No longer recruiting·A study of exercise compared to health promotion in 35 -45 year old men with elevated cardiovascular risk
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Shiga toxin-associated hemolytic uremic syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Shiga toxin-associated hemolytic uremic syndrome" OR "D+ HUS" OR "EHEC-HUS" OR "Hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli" OR "Hemolytic uremic syndrome with diarrhea" OR "STEC-HUS" OR "Shiga-like toxin-associated HUS" OR "Stx-HUS" OR "Typical HUS" OR "Typical hemolytic uremic syndrome" OR "D+HUS" OR "STEC Hemolytic Uremic Syndrome" OR "Sxt-HUS" OR "hemolytic-uremic syndrome with diarrhea" OR "hemolytic-uremic syndrome with diarrhoea" OR "typical hemolytic-uremic syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Shiga toxin-associated hemolytic uremic syndrome" OR "D+ HUS" OR "EHEC-HUS" OR "Hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli" OR "Hemolytic uremic syndrome with diarrhea" OR "STEC-HUS" OR "Shiga-like toxin-associated HUS" OR "Stx-HUS" OR "Typical HUS" OR "Typical hemolytic uremic syndrome" OR "D+HUS" OR "STEC Hemolytic Uremic Syndrome" OR "Sxt-HUS" OR "hemolytic-uremic syndrome with diarrhea" OR "hemolytic-uremic syndrome with diarrhoea" OR "typical hemolytic-uremic syndrome"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 3 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hemolytic-uremic syndrome"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1758) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T03:30:56.007Z
